Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948)
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948)
Authors
Keywords
Biomarkers, Sarcomas, Placental growth factor, Blood plasma, Immunostaining, Cancer treatment, Enzyme-linked immunoassays, VEGF signaling
Journal
PLoS One
Volume 7, Issue 2, Pages e26331
Publisher
Public Library of Science (PLoS)
Online
2012-02-08
DOI
10.1371/journal.pone.0026331
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CXCL12 (SDF1 )-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?
- (2011) D. G. Duda et al. CLINICAL CANCER RESEARCH
- Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway
- (2010) Chang-Liang Peng et al. CANCER BIOLOGY & THERAPY
- Exploratory Analysis of Early Toxicity of Sunitinib in Advanced Hepatocellular Carcinoma Patients: Kinetics and Potential Biomarker Value
- (2010) A. X. Zhu et al. CLINICAL CANCER RESEARCH
- Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2010) C. Pena et al. CLINICAL CANCER RESEARCH
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide
- (2010) Elizabeth R. Gerstner et al. JOURNAL OF NEURO-ONCOLOGY
- Interstitial Fluid Pressure as a Prognostic Factor in Cervical Cancer Following Radiation Therapy
- (2009) S.-G. Yeo et al. CLINICAL CANCER RESEARCH
- Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
- (2009) Christopher G. Willett et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
- (2009) Robert G. Maki et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers of response and resistance to antiangiogenic therapy
- (2009) Rakesh K. Jain et al. Nature Reviews Clinical Oncology
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Early development of sunitinib in hepatocellular carcinoma
- (2008) Andrew X Zhu et al. Expert Review of Anticancer Therapy
- Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate
- (2008) Youichi Ogawa et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More